Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

BACKGROUND: Since lifestyle changes are main therapies for non-alcoholic fatty liver disease (NAFLD), changing dietary components (nutritional or bioactive) may play a parallel important role. Few studies have assessed the effects of curcumin on NAFLD (mainly antioxidant and anti-inflammatory effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazayeri-Tehrani, Seyed Ali, Rezayat, Seyed Mahdi, Mansouri, Siavash, Qorbani, Mostafa, Alavian, Seyed Moayed, Daneshi-Maskooni, Milad, Hosseinzadeh-Attar, Mohammad-Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348610/
https://www.ncbi.nlm.nih.gov/pubmed/30705687
http://dx.doi.org/10.1186/s12986-019-0331-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348610/
https://www.ncbi.nlm.nih.gov/pubmed/30705687
http://dx.doi.org/10.1186/s12986-019-0331-1

Ejemplares similares